JP2024532677A5 - - Google Patents

Info

Publication number
JP2024532677A5
JP2024532677A5 JP2024505333A JP2024505333A JP2024532677A5 JP 2024532677 A5 JP2024532677 A5 JP 2024532677A5 JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024505333 A JP2024505333 A JP 2024505333A JP 2024532677 A5 JP2024532677 A5 JP 2024532677A5
Authority
JP
Japan
Prior art keywords
moiety
oligo
auristatin
cancer
berotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532677A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2022/050782 external-priority patent/WO2023007481A1/en
Publication of JP2024532677A publication Critical patent/JP2024532677A/ja
Publication of JP2024532677A5 publication Critical patent/JP2024532677A5/ja
Pending legal-status Critical Current

Links

JP2024505333A 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用 Pending JP2024532677A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL285208 2021-07-28
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532677A JP2024532677A (ja) 2024-09-10
JP2024532677A5 true JP2024532677A5 (https=) 2025-07-23

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505333A Pending JP2024532677A (ja) 2021-07-28 2022-07-20 水溶性プロドラッグ、複合体およびその使用

Country Status (7)

Country Link
EP (1) EP4377292A1 (https=)
JP (1) JP2024532677A (https=)
CN (1) CN117999254A (https=)
AU (1) AU2022318483A1 (https=)
CA (1) CA3226393A1 (https=)
IL (1) IL310354A (https=)
WO (1) WO2023007481A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701128YA (en) * 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN120682290A (zh) * 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
JP7708662B2 (ja) * 2018-10-24 2025-07-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法

Similar Documents

Publication Publication Date Title
CN111295389B (zh) 生物活性物偶联物及其制备方法和用途
JP7403507B2 (ja) 薬物としてアマトキシンの誘導体を有する抗体薬物コンジュゲート
JP6871858B2 (ja) 抗体薬物コンジュゲート
CN106255513B (zh) 用于药物偶联物的含磺酰胺连接系统
BR112021004656A2 (pt) conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo
JP2022530524A5 (https=)
ES2821878T3 (es) Conectores autoinmolativos no lineales y conjugados de los mismos
JP2022547434A (ja) 標的化デンドリマー複合体
CN107614488A (zh) 新型亲水连接体和其在配体‑药物共轭偶联物上的应用
JPH02191300A (ja) 抗体―薬物抱合体
WO2024235136A9 (zh) 杂环类化合物及其制备方法和用途
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2024532677A5 (https=)
WO2024235134A9 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2024529466A5 (https=)
WO2024235130A1 (zh) 多环化合物及其制备方法和用途
WO2024235133A9 (zh) 多环类药物偶联物及其制备方法和用途
JP7753523B2 (ja) Sn38を含む抗体-薬物コンジュゲートの中間体及びその調製方法
JP2026508115A (ja) リンカー薬物、その抗体-薬物コンジュゲート、並びにそれらの調製方法及び使用
JP2025514436A (ja) 親水性糖構造を含むリガンド薬物複合体
JP2025507707A (ja) 新規の抗体薬剤コンジュゲート
WO2025232688A1 (zh) 并环类药物偶联物及其制备方法和用途
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
JP2025532285A (ja) 高安定性親水性リンカーユニットを有するアウリスタチン系薬物及びその複合体
WO2024235135A1 (zh) 大环化合物及其制备方法和用途